Clinics & Hospitals

RetinAI Discovery® Platform - Unlocking the Power of Data

Today, many healthcare providers are forced to navigate a sea of unstructured and disorganized patient data. From a clinical and research standpoint, this lack of structure and accessibility limits the extent to which organizations can develop their daily routine work.

RetinAI has developed a data management platform to efficiently process data at scale across imaging types and devices. At the simple press of a keystroke, healthcare professionals can navigate imaging data, compute imaging biomarkers and track changes over time for some of the most common forms of eye diseases through a web browser.

RetinAI Discovery® uses unique medical image and data management to organize and structure the information generated routinely in a clinic or during a clinical study. AI models provide insights on biomarkers and automatic segmentation and quantification layers and fluid in retinal pathologies.

Researchers and clinicians can track changes in volumes and obtain measurements of these imaging biomarkers over multiple timepoints, saving valuable effort in assessing disease progression in a single working environment.

Interested in learning more?


RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.

The AI modules for biomarkers, fluid and layer segmentation and quantification
in retinal pathologies are for research use only in the USA.
The Advanced Segmentation and GA modules are for research use only.
Please be advised these tools are not intended to be a substitute for medical advice, diagnosis or treatment.
We do not warrant any reliance on the accuracy, completeness or usefulness of any content.